For people living with Becker muscular dystrophy, the trajectory of the disease has always pointed in one direction: down. Muscles weaken slowly but relentlessly. Walking becomes harder. Climbing stairs becomes impossible. Heart and breathing muscles weaken too, eventually. And until today, no drug in the world had ever been approved to change that course.
That may now be about to change.
On March 10, 2026, Edgewise Therapeutics announced that **sevasemten** — an investigational drug targeting a protein involved in muscle contraction — has demonstrated **sustained functional stabilisation in Becker muscular dystrophy patients for 3.5 years**. The long-term data comes from the MESA open-label extension study, the longest continuous follow-up of any treatment candidate for this disease.
The finding is not a cure. But for a condition where progression is the only previously available outcome, three and a half years of stability is nothing short of remarkable — and the data supports moving to pivotal trials.
**What Is Becker Muscular Dystrophy?**
Becker muscular dystrophy (BMD) is a genetic disorder caused by mutations in the dystrophin gene — the same gene affected in the more severe Duchenne muscular dystrophy (DMD). In BMD, the mutations allow a partially functional dystrophin protein to be produced, which means progression is typically slower than Duchenne but still causes progressive muscle weakness, often beginning in the teens or twenties.
The condition affects approximately **1 in 18,000–30,000 males**, though it also rarely affects females. Symptoms include difficulty running and climbing stairs, exercise intolerance, muscle cramps, and eventually cardiomyopathy — a weakening of the heart muscle that is the leading cause of death in BMD patients, typically in their 40s or 50s.
Unlike Duchenne — for which several therapies including exon-skipping approaches have received regulatory approval — **Becker muscular dystrophy has no approved disease-modifying treatments**. Patients are managed with corticosteroids (which have significant side effects), physical therapy, cardiac monitoring, and supportive care. The underlying progression of the disease has never, until now, been demonstrably halted.
**What Sevasemten Does**
Sevasemten is a **fast skeletal myosin inhibitor** — a drug that works not by repairing the broken dystrophin protein, but by addressing a downstream consequence of its absence.
In Becker and Duchenne muscular dystrophy, muscles lacking adequate dystrophin are highly susceptible to damage from normal contraction. Every time the muscle contracts — during exercise, walking, even normal daily activity — the unprotected muscle fibres experience micro-tears that, over time, cause cumulative degeneration. Sevasemten targets the fast-twitch skeletal myosin protein, modulating the force and velocity of muscle contractions to reduce this contraction-induced damage.
The goal is not to make muscles stronger in the traditional sense, but to protect them from the very mechanism causing their deterioration.
**The MESA Results**
The MESA open-label extension study followed participants treated with sevasemten over an extended period. The 3.5-year data presented today showed that participants maintained stable physical function — measured by standardised assessments of walking distance, climbing ability, and functional strength — throughout the follow-up period.
In the natural history of Becker muscular dystrophy, meaningful functional decline is expected over this timeframe in untreated patients. The stabilisation observed in MESA represents a statistically significant deviation from that expected course.
'Participants treated with sevasemten experienced a stabilisation of function over 3.5 years,' Edgewise noted in its announcement, 'in marked contrast to the expected functional decline associated with Becker, a devastating genetic disorder for which no approved therapeutic interventions currently exist.'
Edgewise has indicated that these results support advancing sevasemten into a pivotal Phase 3 trial — the final stage before a regulatory submission for approval.
**A Disease That Has Waited Long Enough**
For BMD patients and their families, the announcement lands differently than it might for conditions already served by multiple therapies. Becker muscular dystrophy is often described as the 'forgotten brother' of Duchenne — less severe, and therefore historically receiving less research attention and investment.
But less severe is not mild. The impact on quality of life is profound. Young men who notice weakness in their twenties face decades of progressive limitation, cardiac complications, and the particular cruelty of watching a body they cannot protect slowly fail.
Sevasemten, if Phase 3 confirms these results and regulatory approval follows, would be the first ever disease-modifying therapy for Becker muscular dystrophy. Not just a treatment. The first treatment.
For an entire patient community that has been waiting for precisely this, March 10, 2026 is a day worth marking. 💪
*Sources: Edgewise Therapeutics (PR Newswire, March 10, 2026) · MESA open-label extension study · Muscular Dystrophy Association · National Institute of Neurological Disorders and Stroke · Duchenne UK*
